1
|
Pessetto ZY, Yan Y, Bessho T, Natarajan A. Erratum to: Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option. Breast Cancer Res Treat 2016; 155:613. [PMID: 26883325 DOI: 10.1007/s10549-016-3702-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- Ziyan Yuan Pessetto
- Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
| | - Ying Yan
- Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE, 68198, USA
| | - Tadayoshi Bessho
- Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE, 68198, USA
| | - Amarnath Natarajan
- Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
- Department of Genetics Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
| |
Collapse
|
2
|
Wu M, Sun L, Pessetto ZY, Zang Z, Xie X, Zhong L, Su Q, Zan W, Gao X, Zhao Y, Sun Y. Casitas B-Lineage Lymphoma RING Domain Inhibitors Protect Mice against High-Fat Diet-Induced Obesity and Insulin Resistance. PLoS One 2015; 10:e0135916. [PMID: 26296084 PMCID: PMC4546618 DOI: 10.1371/journal.pone.0135916] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2014] [Accepted: 07/28/2015] [Indexed: 02/05/2023] Open
Abstract
The casitas b-lineage lymphoma (c-Cbl) is an important adaptor protein with an intrinsic E3 ubiquitin ligase activity that interacts with E2 proteins such as UbCH7. c-Cbl plays a vital role in regulating receptor tyrosine kinase signaling. c-Cbl involves in whole-body energy homeostasis, which makes it a potential target for the treatment of type 2 diabetes and obesity. In the present study, we have designed two parental peptides and 55 modified peptides based on the structure of UbCH7 loop L1 and L2. Thirteen of the modified peptides showed increased inhibitory activity in a fluorescence polarization-based assay. In the in vivo proof of study principle, mice treated with peptides 10, 34, 49 and 51 were protected against high-fat diet-induced obesity and insulin resistant. These inhibitors may potentially lead to new therapeutic alternatives for obesity and type 2 diabetes.
Collapse
Affiliation(s)
- Min Wu
- Department of Pharmacy, Chengdu Medical College. Chengdu, Sichuan Province, China
| | - Lin Sun
- West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
| | - Ziyan Yuan Pessetto
- Department of Pathology and Laboratory Medicine, Univerisity of Kansas Medical Center, Kansas City, KS, United States of America
| | - Zhihe Zang
- Department of Pharmacy, Chengdu Medical College. Chengdu, Sichuan Province, China
| | - Xingliang Xie
- Department of Pharmacy, Chengdu Medical College. Chengdu, Sichuan Province, China
| | - Ling Zhong
- Department of Pharmacy, Chengdu Medical College. Chengdu, Sichuan Province, China
| | - Qing Su
- Department of Pharmacy, Chengdu Medical College. Chengdu, Sichuan Province, China
| | - Wang Zan
- Department of Pharmacy, Chengdu Medical College. Chengdu, Sichuan Province, China
| | - Xiurong Gao
- Department of Pharmacy, Chengdu Medical College. Chengdu, Sichuan Province, China
| | - Yan Zhao
- Department of Pharmacy, Chengdu Medical College. Chengdu, Sichuan Province, China
| | - Yiyi Sun
- Department of Pharmacy, Chengdu Medical College. Chengdu, Sichuan Province, China
- * E-mail:
| |
Collapse
|
3
|
Xie X, Sun L, Pessetto ZY, Zhao Y, Zang Z, Zhong L, Wu M, Su Q, Gao X, Zan W, Sun Y. Development of a fluorescence polarization based high-throughput assay to identify Casitas B-lineage lymphoma RING domain regulators. PLoS One 2013; 8:e78042. [PMID: 24205080 PMCID: PMC3814989 DOI: 10.1371/journal.pone.0078042] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2013] [Accepted: 09/17/2013] [Indexed: 12/12/2022] Open
Abstract
The E3 ubiquitin protein ligase Casitas B-lineage Lymphoma (Cbl) proteins and their binding partners play an important role in regulating signal transduction pathways. It is important to utilize regulators to study the protein-protein interactions (PPIs) between these proteins. However, finding specific small-molecule regulators of PPIs remains a significant challenge due to the fact that the interfaces involved in PPIs are not well suited for effective small molecule binding. We report the development of a competitive, homogeneous, high-throughput fluorescence polarization (FP) assay to identify small molecule regulators of Cbl (RING) domain. The FP assay was used to measure binding affinities and inhibition constants of UbCH7 peptides and small molecule regulators of Cbl (RING) domains, respectively. In order to rule out promiscuous, aggregation-based inhibition, two assay conditions were developed and compared side by side. Under optimized conditions, we screened a 10,000 natural compound library in detergent-free and detergent-present (0.01% Triton X-100) systems. The results indicate that the detergent-present system is more suitable for high-throughput screens. Three potential compounds, methylprotodioscin, leonuride and catalpol, have been identified that bind to Cbl (RING) domain and interfere with the Cbl (RING)-UbCH7 protein-protein interaction.
Collapse
Affiliation(s)
- Xingliang Xie
- Department of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Lin Sun
- West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
| | - Ziyan Yuan Pessetto
- Department of Pathology & Laboratory Medicine, Univerisity of Kansas Medical Center, Kansas City, Kansasa, United States of America
| | - Yan Zhao
- Department of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Zhihe Zang
- Department of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Ling Zhong
- Department of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Min Wu
- Department of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Qing Su
- Department of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Xiurong Gao
- Department of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Wang Zan
- Department of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
| | - Yiyi Sun
- Department of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China
- * E-mail:
| |
Collapse
|
4
|
Pessetto ZY, Yan Y, Bessho T, Natarajan A. Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option. Breast Cancer Res Treat 2012; 134:511-517. [PMID: 22562176 PMCID: PMC3402595 DOI: 10.1007/s10549-012-2079-4#page-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2012] [Accepted: 04/21/2012] [Indexed: 07/19/2023]
Abstract
Synthetic lethal therapeutic strategy using poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor olaparib in carriers of BRCA1 or BRCA2 mutation has shown promise in clinical settings. Since <5 % of patients are BRCA1 or BRCA2 mutation carriers, small molecules that functionally mimic BRCA1 or BRCA2 mutations will extend the synthetic lethal therapeutic option for non-mutation carriers. Here we provide proof of principle for this strategy using a BRCA1 inhibitor peptide 2 that targets the BRCT(BRCA1)-phosphoprotein interaction and mimics the M177R/K BRCA1 mutation. Reciprocal immunoprecipitation and immunoblotting of BRCA1 and Abraxas was used to demonstrate inhibitor 2 targets BRCT(BRCA1)-Abraxas interface. Immunostaining of γH2AX, cell cycle analysis and homologous recombination (HR) assays were conducted to confirm that inhibitor 2 functionally mimics a chemosensitizing BRCA1 mutation. The concept of synthetic lethal therapeutic strategy with the BRCA1 inhibitor 2 and the PARP inhibitor Olaparib was explored in HeLa, MDA-MB-231, and HCC1937 cell lines. The results show that inhibition of BRCA1 by 2 sensitizes HeLa and MDA-MB-231 cells but not HCC1937 to Olaparib mediated growth inhibition and apoptosis. These results provide the basis for developing high affinity BRCT(BRCA1) inhibitors as adjuvants to treat sporadic breast and ovarian cancers.
Collapse
Affiliation(s)
- Ziyan Yuan Pessetto
- Eppley Institute for Cancer Research, University of Nebraska Medical Center Omaha NE 68198
| | - Ying Yan
- Eppley Institute for Cancer Research, University of Nebraska Medical Center Omaha NE 68198, (402) 559-3036
| | - Tadayoshi Bessho
- Eppley Institute for Cancer Research, University of Nebraska Medical Center Omaha NE 68198, (402) 559-7018
| | - Amarnath Natarajan
- Eppley Institute for Cancer Research, Department of Pharmaceutical Sciences and Genetics Cell Biology and Anatomy, University of Nebraska Medical Center Omaha NE 68198, Telephone: (402) 559 3793, Fax number: (402) 559 8270
| |
Collapse
|